Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Zisowsky

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Pharmaceutics|October 11, 2016
Drug Development for Pediatric Populations: Regulatory AspectsJochen Zisowsky, Andreas Krause, Jasper Dingemanse
Pulmonary Pharmacology & Therapeutics|March 5, 2018
Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertensionAndreas Krause, Jochen Zisowsky, Jasper Dingemanse
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2026
Concentration response analyses for QT data with several active compoundsGünter Heimann, Giulia Lestini, Jochen Zisowsky
European Journal of Clinical Pharmacology|January 25, 2014
Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhageJochen Zisowsky, Eliane Fuseau, Shirin Bruderer, et al.
Pharmacology|February 4, 2012
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjectsMatthias Hoch, Petra Hoever, Jochen Zisowsky, et al.
Paediatric Drugs|January 13, 2017
Pediatric Development of Bosentan Facilitated by Modeling and SimulationJochen Zisowsky, Martine Géhin, Andjela Kusic-Pajic, et al.
International Journal of Cancer|September 24, 2004
Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistanceAnamaria Brozovic, Gerhard Fritz, Markus Christmann, et al.
Biochemical Pharmacology|November 14, 2006
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cellsJochen Zisowsky, Susanne Koegel, Stefan Leyers, et al.
British Journal of Clinical Pharmacology|May 3, 2020
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intakeAnne Keunecke, Sven Hoefman, Henk-Jan Drenth, et al.
Anti-Cancer Drugs|January 19, 2005
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell linesMartina Heim, Mariam Scharifi, Jochen Zisowsky, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Pharmaceutics|October 11, 2016
Drug Development for Pediatric Populations: Regulatory AspectsJochen Zisowsky, Andreas Krause, Jasper Dingemanse
Pulmonary Pharmacology & Therapeutics|March 5, 2018
Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertensionAndreas Krause, Jochen Zisowsky, Jasper Dingemanse
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2026
Concentration response analyses for QT data with several active compoundsGünter Heimann, Giulia Lestini, Jochen Zisowsky
European Journal of Clinical Pharmacology|January 25, 2014
Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhageJochen Zisowsky, Eliane Fuseau, Shirin Bruderer, et al.
Pharmacology|February 4, 2012
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjectsMatthias Hoch, Petra Hoever, Jochen Zisowsky, et al.
Paediatric Drugs|January 13, 2017
Pediatric Development of Bosentan Facilitated by Modeling and SimulationJochen Zisowsky, Martine Géhin, Andjela Kusic-Pajic, et al.
International Journal of Cancer|September 24, 2004
Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistanceAnamaria Brozovic, Gerhard Fritz, Markus Christmann, et al.
Biochemical Pharmacology|November 14, 2006
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cellsJochen Zisowsky, Susanne Koegel, Stefan Leyers, et al.
British Journal of Clinical Pharmacology|May 3, 2020
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intakeAnne Keunecke, Sven Hoefman, Henk-Jan Drenth, et al.
Anti-Cancer Drugs|January 19, 2005
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell linesMartina Heim, Mariam Scharifi, Jochen Zisowsky, et al.
Pageof 2